Stopping RA medicines in combination therapy
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This study looks at whether people with rheumatoid arthritis who are stable on a TNF inhibitor plus another drug can safely stop the second drug. It aims to see if stopping the extra medicine keeps the disease under control and reduces side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have rheumatoid arthritis, diagnosed by a doctor.
- Your disease has been stable (low activity) for at least 6 months.
- You are currently taking a TNF inhibitor (a type of biologic drug) and either methotrexate or leflunomide.
- You have been on a stable dose of your TNF inhibitor for at least 6 months and your other medicine for at least 3 months.
- You are not pregnant, breastfeeding, or planning pregnancy during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two different ways of slowly lowering the dose of steroids (like prednisolone) in people with stable rheumatoid arthritis. The goal is to see which tapering schedule is safer and more effective, possibly reducing side effects while keeping the disease under control.
This study tests whether a lower dose (200 mg) of rituximab given every 6 months is effective for maintaining control of rheumatoid arthritis. It is for people who are already on rituximab maintenance therapy and have low to moderate disease activity.
This trial tests a medical device to help people with rheumatoid arthritis stay in remission while on biologic therapy. The goal is to see if the device can prevent flares and maintain disease control.
This study follows people with rheumatoid arthritis (RA) who have achieved remission—meaning their disease is well-controlled—to see how safely doctors can reduce or stop their medications over time. You would be monitored regularly to ensure your RA stays in remission.
This study compares two combination treatments for rheumatoid arthritis in people whose current methotrexate or leflunomide isn’t working well enough. It aims to see whether adding a targeted therapy works better than the standard add-on of sulfasalazine plus hydroxychloroquine.
This Phase 3 study compares two ways to treat active rheumatoid arthritis: a TNF-blocking biologic versus a targeted pill treatment. It may help people who are not doing well on (or cannot tolerate) certain biologic therapies to find a better, more practical option.
Hear when a new Rheumatoid Arthritis (RA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.